$ZEOX
Zeo ScientifiX, Inc. Stock $zeox

$zeox Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000182912624000541 Filed on January 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.154M	$1.422M	$4.558M
YoY Change	7.83%	-1.5%	-29.78%
Cost Of Revenue	$159.0K	$132.9K	$507.6K
YoY Change	52.43%	-50.64%	-32.63%
Gross Profit	$995.0K	$1.289M	$4.051M
YoY Change	3.01%	9.77%	-29.4%
Gross Profit Margin	86.22%	90.65%	88.86%
Selling, General & Admin	$2.157M	$2.521M	$10.82M
YoY Change	-31.35%	-42.12%	-25.81%
% of Gross Profit	216.78%	195.55%	267.06%
Research & Development	$27.00K		$922.7K
YoY Change	-86.13%		16.6%
% of Gross Profit	2.71%		22.78%
Depreciation & Amortization	$19.00K	$16.49K	$486.4K
YoY Change	-87.8%	-93.73%	46.27%
% of Gross Profit	1.91%	1.28%	12.01%
Operating Expenses	$27.00K	$2.521M	$922.7K
YoY Change	-86.13%	-42.12%	16.6%
Operating Profit	-$1.162M	-$1.232M	-$6.767M
YoY Change	-46.61%	-61.28%	-23.48%
Interest Expense	$27.00K	-$90.02K	$431.4K
YoY Change	-55.71%	19.91%	8.33%
% of Operating Profit
Other Income/Expense, Net	$149.0K	-$10.00K	-$10.00K
YoY Change	-401.68%	-104.23%	-104.01%
Pretax Income	-$1.040M	-$1.091M	-$6.987M
YoY Change	-54.52%	-63.87%	-21.47%
Income Tax
% Of Pretax Income
Net Earnings	-$1.040M	-$1.091M	-$6.987M
YoY Change	-54.52%	-63.87%	-21.47%
Net Earnings / Revenue	-90.12%	-76.73%	-153.28%
Basic Earnings Per Share	-$0.17		-$0.99
Diluted Earnings Per Share	-$0.17	-$0.16	-$0.99
COMMON SHARES
Basic Shares Outstanding	6.125M shares		7.029M shares
Diluted Shares Outstanding	6.191M shares		7.029M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.172M	$1.756M	$1.756M
YoY Change	-17.61%	-53.21%	-53.21%
Cash & Equivalents	$1.172M	$1.756M
Short-Term Investments
Other Short-Term Assets	$315.0K	$106.2K	$106.2K
YoY Change	-55.93%	-38.68%	-38.68%
Inventory	$316.0K	$310.2K	$310.2K
Prepaid Expenses	$315.0K	$106.2K
Receivables	$77.00K	$18.21K	$18.21K
Other Receivables	$12.00K	$11.38K	$11.38K
Total Short-Term Assets	$1.892M	$2.202M	$2.202M
YoY Change	-28.67%	-49.56%	-49.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$533.0K	$572.7K	$572.7K
YoY Change	-65.48%	-65.98%	-68.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.000K	$7.320K	$7.320K
YoY Change	-76.97%	-81.67%	-81.67%
Total Long-Term Assets	$540.0K	$580.0K	$580.0K
YoY Change	-67.58%	-68.38%	-68.38%
TOTAL ASSETS
Total Short-Term Assets	$1.892M	$2.202M	$2.202M
Total Long-Term Assets	$540.0K	$580.0K	$580.0K
Total Assets	$2.432M	$2.782M	$2.782M
YoY Change	-43.67%	-55.13%	-55.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.219M	$2.612M	$2.612M
YoY Change	-2.18%	9.81%	9.81%
Accrued Expenses		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$663.0K	$656.9K	$656.9K
YoY Change		16.65%	16.65%
Long-Term Debt Due	$663.0K	$656.9K	$23.11K
YoY Change		16.65%	-83.92%
Total Short-Term Liabilities	$3.923M	$4.010M	$4.010M
YoY Change	14.51%	-1.31%	-1.31%
LONG-TERM LIABILITIES
Long-Term Debt	$17.00K	$13.13K	$13.13K
YoY Change	-91.82%	-94.04%	-94.04%
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$17.00K	$13.13K	$13.13K
YoY Change	-92.09%	-94.73%	-94.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.923M	$4.010M	$4.010M
Total Long-Term Liabilities	$17.00K	$13.13K	$13.13K
Total Liabilities	$3.940M	$4.023M	$4.023M
YoY Change	8.22%	-6.7%	-6.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.55M	-$57.51M
YoY Change	10.87%	13.83%
Common Stock	$6.000K	$7.284K
YoY Change	-99.6%	-99.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.508M	-$1.241M	-$1.241M
YoY Change
Total Liabilities & Shareholders Equity	$2.432M	$2.782M	$2.782M
YoY Change	-43.67%	-55.13%	-55.13%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.040M	-$1.091M	-$6.987M
YoY Change	-54.52%	-63.87%	-21.47%
Depreciation, Depletion And Amortization	$19.00K	$16.49K	$486.4K
YoY Change	-87.8%	-93.73%	46.27%
Cash From Operating Activities	-$575.0K	$220.5K	-$2.197M
YoY Change	-55.17%	-112.54%	-30.59%
INVESTING ACTIVITIES
Capital Expenditures		$5.730K	$25.39K
YoY Change		-98.14%	-96.92%
Acquisitions
YoY Change
Other Investing Activities		$741.0K	$641.0K
YoY Change
Cash From Investing Activities		$735.2K	$615.6K
YoY Change		-338.54%	-174.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$100.0K
YoY Change			-98.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$9.000K	166.9K	-$415.2K
YoY Change	-99.13%	-97.09%	-105.44%
NET CHANGE
Cash From Operating Activities	-$575.0K	220.5K	-$2.197M
Cash From Investing Activities		735.2K	$615.6K
Cash From Financing Activities	-$9.000K	166.9K	-$415.2K
Net Change In Cash	-$584.0K	1.123M	-$1.997M
YoY Change	-74.94%	-69.48%	-154.79%
FREE CASH FLOW
Cash From Operating Activities	-$575.0K	$220.5K	-$2.197M
Capital Expenditures		$5.730K	$25.39K
Free Cash Flow	-$575.0K	$214.7K	-$2.223M
YoY Change	-55.73%	-110.39%	-44.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001557376
CY2023Q4	OCEL	Receivables From Related Parties ReceivablesFromRelatedParties		usd
CY2023Q4	us-gaap	Other Assets OtherAssets		usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability		usd
CY2023Q4	OCEL	Promissory Note Net Of Debt Discount PromissoryNoteNetOfDebtDiscount		usd
CY2022Q4	OCEL	Convertible Promissory Note Net Of Debt Discount ConvertiblePromissoryNoteNetOfDebtDiscount		usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation		usd
CY2023Q4	OCEL	Commitment To Repurchase Shares In Connection With Settlement Of Litigation CommitmentToRepurchaseSharesInConnectionWithSettlementOfLitigation		usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022	OCEL	Impairment Of Nonmarketable Securities In Related Entity ImpairmentOfNonmarketableSecuritiesInRelatedEntity		usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets		usd
CY2023	OCEL	Gain From Writeoff Of Liabilities Attributable To Discontinued Operations GainFromWriteoffOfLiabilitiesAttributableToDiscontinuedOperations		usd
CY2022	OCEL	Shares Issued In Restructuring SharesIssuedInRestructuring		usd
CY2023	OCEL	Cancellation Of Shares Repurchased In Connection With Litigation CancellationOfSharesRepurchasedInConnectionWithLitigation		usd
CY2023	OCEL	Return Of Former Executives Shares And Warrants ReturnOfFormerExecutivesSharesAndWarrants		usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets		usd
CY2023	OCEL	Gain From Writeoff Of Liabilities Attributable To Discontinued Operations GainFromWriteoffOfLiabilitiesAttributableToDiscontinuedOperations		usd
CY2023	OCEL	Gain From Writeoffs And Settlements Of Accounts Payable And Notes Payable GainFromWriteoffsAndSettlementsOfAccountsPayableAndNotesPayable		usd
CY2022	OCEL	Writeoff Of Nonmarketable Securities WriteoffOfNonmarketableSecurities		usd
CY2022	OCEL	Writeoff Of Receivables From Officers And Other Receivable WriteoffOfReceivablesFromOfficersAndOtherReceivable		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023	OCEL	Reserve For Bad Debt ReserveForBadDebt		usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2023	OCEL	Stocks Issued In Settlement Of Litigation StocksIssuedInSettlementOfLitigation		usd
CY2023	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties		usd
CY2023	OCEL	Increase Decrease In Accrued Liabilities To Management IncreaseDecreaseInAccruedLiabilitiesToManagement		usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022	OCEL	Investment In Nonmarketable Equity Securities InvestmentInNonmarketableEquitySecurities		usd
CY2022	OCEL	Shares Repurchased In Connection With Litigation SharesRepurchasedInConnectionWithLitigation		usd
CY2023	OCEL	Capital Contributed By Executive CapitalContributedByExecutive		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	OCEL	Executive Forgiveness Of Employment Obligation In Connections With Restructuring ExecutiveForgivenessOfEmploymentObligationInConnectionsWithRestructuring		usd
CY2023	OCEL	Warrants Issued To Executives As Payment For Outstandings Compensation WarrantsIssuedToExecutivesAsPaymentForOutstandingsCompensation		usd
CY2022	OCEL	Warrants Issued In Connection With Convertible Notes WarrantsIssuedInConnectionWithConvertibleNotes		usd
CY2022	OCEL	Finance Lease Assigned To Buyer In Connection With Asset Sale FinanceLeaseAssignedToBuyerInConnectionWithAssetSale		usd
CY2023	OCEL	Stock Issued In Exchange For Accounts Payable StockIssuedInExchangeForAccountsPayable		usd
CY2023	OCEL	Stock Purchased From Payments Due On Accounts Payable StockPurchasedFromPaymentsDueOnAccountsPayable		usd
CY2023	OCEL	Commitment Fee Shortfall Obligation CommitmentFeeShortfallObligation		usd
CY2023	OCEL	Commitment To Repurchase Share In Connections With Settlement Of Litigation CommitmentToRepurchaseShareInConnectionsWithSettlementOfLitigation		usd
CY2023	OCEL	Promissory Note Issued For Past Due Professional Fees PromissoryNoteIssuedForPastDueProfessionalFees		usd
CY2023	OCEL	Purchase Of Fixed Assets Included In Accounts Payable PurchaseOfFixedAssetsIncludedInAccountsPayable		usd
CY2022	OCEL	Common Stock Issued In Satisfaction Of Commitment Fee Shortfall Obligation CommonStockIssuedInSatisfactionOfCommitmentFeeShortfallObligation		usd
CY2022Q4	OCEL	Equity In Nonmarketable Securities EquityInNonmarketableSecurities		usd
CY2022Q4	OCEL	Reserve On Carrying Value Of Investment In Nonmarketable Securities ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities		usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023Q4	OCEL	Securities Purchase Agreement22 SecuritiesPurchaseAgreement22		usd
CY2023Q4	OCEL	Securities Purchase Agreement23 SecuritiesPurchaseAgreement23		usd
CY2022Q4	OCEL	Securities Purchase Agreement23 SecuritiesPurchaseAgreement23		usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential		usd
CY2023	OCEL	Executive Forgiveness Of Employment Obligations In Connections With Restructuring ExecutiveForgivenessOfEmploymentObligationsInConnectionsWithRestructuring		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2022	OCEL	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeiture In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitureInPeriod		shares
CY2022	OCEL	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-10-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--10-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55008
CY2023	dei	Entity Registrant Name EntityRegistrantName	ORGANICELL REGENERATIVE MEDICINE, INC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4180540
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3321 College Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 246
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Davie
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33314
CY2023	dei	City Area Code CityAreaCode	(888)
CY2023	dei	Local Phone Number LocalPhoneNumber	963-7881
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	7197268	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6125482	shares
CY2023	dei	Auditor Name AuditorName	Weinberg & Company P.A.
CY2023	dei	Auditor Firm AuditorFirmId	572
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, CA
CY2023Q4	us-gaap	Cash Cash	1756202	usd
CY2022Q4	us-gaap	Cash Cash	3753097	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18212	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	55110	usd
CY2022Q4	OCEL	Receivables From Related Parties ReceivablesFromRelatedParties	128939	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	11378	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	7433	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	106184	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	173152	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	310183	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	248510	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2202159	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4366241	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	572726	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1683516	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	110995	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	7315	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	39936	usd
CY2023Q4	us-gaap	Assets Assets	2782200	usd
CY2022Q4	us-gaap	Assets Assets	6200688	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2611969	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2378531	usd
CY2023Q4	OCEL	Advances Payable To Former Officer AdvancesPayableToFormerOfficer	220897	usd
CY2022Q4	OCEL	Advances Payable To Former Officer AdvancesPayableToFormerOfficer	220897	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	23107	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	143748	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	82407	usd
CY2022Q4	OCEL	Promissory Note Net Of Debt Discount PromissoryNoteNetOfDebtDiscount	563111	usd
CY2023Q4	OCEL	Convertible Promissory Note Net Of Debt Discount ConvertiblePromissoryNoteNetOfDebtDiscount	656853	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	174462	usd
CY2022Q4	OCEL	Commitment To Repurchase Shares In Connection With Settlement Of Litigation CommitmentToRepurchaseSharesInConnectionWithSettlementOfLitigation	500000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	497259	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4010085	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4063156	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	13134	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	220340	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28588	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4023219	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4312084	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7283483	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7283483	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7395632	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7395632	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7284	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7396	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	56259711	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	52402514	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57508014	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50521306	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1241019	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1888604	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2782200	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6200688	usd
CY2023	OCEL	Revenues From Related Parties RevenuesFromRelatedParties	115440	usd
CY2022	OCEL	Revenues From Related Parties RevenuesFromRelatedParties	329600	usd
CY2023	us-gaap	Revenues Revenues	4558278	usd
CY2022	us-gaap	Revenues Revenues	6491008	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	507629	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	753534	usd
CY2023	us-gaap	Gross Profit GrossProfit	4050649	usd
CY2022	us-gaap	Gross Profit GrossProfit	5737474	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10817627	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14580434	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-6766978	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8842960	usd
CY2023	us-gaap	Interest Expense InterestExpense	431424	usd
CY2022	us-gaap	Interest Expense InterestExpense	398260	usd
CY2023	OCEL	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation	18917	usd
CY2022	OCEL	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation	30692	usd
CY2023	OCEL	Impairment Of Nonmarketable Securities In Related Entity ImpairmentOfNonmarketableSecuritiesInRelatedEntity	100000	usd
CY2023	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	340611	usd
CY2022	OCEL	Gain From Writeoff Of Liabilities Attributable To Discontinued Operations GainFromWriteoffOfLiabilitiesAttributableToDiscontinuedOperations	125851	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	249504	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6986708	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8896557	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.56
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7028638	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7028638	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5688230	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5688230	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2665593	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7290000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3916590	usd
CY2022	OCEL	Capital Contributed By Executives CapitalContributedByExecutives	250000	usd
CY2022	OCEL	Warrants Issued To Executives As Payment For Outstanding Compensation WarrantsIssuedToExecutivesAsPaymentForOutstandingCompensation	649740	usd
CY2022	OCEL	Executive Forgiveness Of Employment Obligations In Connection With Restructuring ExecutiveForgivenessOfEmploymentObligationsInConnectionWithRestructuring	1526893	usd
CY2022	OCEL	Commitment To Repurchase Shares In Connections With Settlement Of Litigation CommitmentToRepurchaseSharesInConnectionsWithSettlementOfLitigation	-500000	usd
CY2022	OCEL	Common Stock Issued As Commitments Fee For Promissory Note CommonStockIssuedAsCommitmentsFeeForPromissoryNote	156231	usd
CY2022	OCEL	Exchange Of Accounts Payable For Stock ExchangeOfAccountsPayableForStock	117500	usd
CY2022	OCEL	Stock Issued In Settlement Of Litigation StockIssuedInSettlementOfLitigation	43800	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8896557	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1888604	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3208776	usd
CY2023	OCEL	Issuance Of Common Stock And Warrants As Commitment Fee For Spa23 Note IssuanceOfCommonStockAndWarrantsAsCommitmentFeeForSpa23Note	282500	usd
CY2023	OCEL	Discount On Warrants Issued With Convertible Debt DiscountOnWarrantsIssuedWithConvertibleDebt	72430	usd
CY2023	OCEL	Stock Issued In Satisfaction Of Commitment Fee Shortfall Obligation StockIssuedInSatisfactionOfCommitmentFeeShortfallObligation	193379	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6986708	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1241019	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6986708	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8896557	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	486354	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	332508	usd
CY2023	OCEL	Amortization Of Oid And Commitment Fee Discount Promissory Note AmortizationOfOidAndCommitmentFeeDiscountPromissoryNote	349272	usd
CY2022	OCEL	Amortization Of Oid And Commitment Fee Discount Promissory Note AmortizationOfOidAndCommitmentFeeDiscountPromissoryNote	323111	usd
CY2023	OCEL	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation	18917	usd
CY2022	OCEL	Change In Commitment Fee Shortfall Obligation ChangeInCommitmentFeeShortfallObligation	30692	usd
CY2023	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	340611	usd
CY2022	OCEL	Gain From Writeoff Of Liabilities Attributable To Discontinued Operations GainFromWriteoffOfLiabilitiesAttributableToDiscontinuedOperations	125851	usd
CY2022	OCEL	Gain From Writeoffs And Settlements Of Accounts Payable And Notes Payable GainFromWriteoffsAndSettlementsOfAccountsPayableAndNotesPayable	249504	usd
CY2023	OCEL	Writeoff Of Nonmarketable Securities WriteoffOfNonmarketableSecurities	100000	usd
CY2023	OCEL	Writeoff Of Receivables From Officers And Other Receivable WriteoffOfReceivablesFromOfficersAndOtherReceivable	142405	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-36219	usd
CY2022	OCEL	Reserve For Bad Debt ReserveForBadDebt	27500	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	37455	usd
CY2022	OCEL	Stocks Issued In Settlement Of Litigation StocksIssuedInSettlementOfLitigation	-43800	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3208776	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3916590	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-36898	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-17148	usd
CY2022	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	128939	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	17411	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	7433	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-66968	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	103505	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	61673	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	51138	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	233439	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1035609	usd
CY2022	OCEL	Increase Decrease In Accrued Liabilities To Management IncreaseDecreaseInAccruedLiabilitiesToManagement	657003	usd
CY2023	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	32621	usd
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-14754	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	497259	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9575	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2197275	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3165840	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25391	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	824743	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	740957	usd
CY2023	OCEL	Investment In Nonmarketable Equity Securities InvestmentInNonmarketableEquitySecurities	100000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	615566	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-824743	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1229400	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	540000	usd
CY2023	OCEL	Shares Repurchased In Connection With Litigation SharesRepurchasedInConnectionWithLitigation	500000	usd
CY2022	OCEL	Capital Contributed By Executive CapitalContributedByExecutive	250000	usd
CY2023	OCEL	Payments On Finance Lease PaymentsOnFinanceLease	114586	usd
CY2022	OCEL	Payments On Finance Lease PaymentsOnFinanceLease	59930	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1130000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	364960	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7270000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-415186	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7635110	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1996895	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3644527	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3753097	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108570	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1756202	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3753097	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	67145	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	78625	usd
CY2022	OCEL	Executive Forgiveness Of Employment Obligation In Connections With Restructuring ExecutiveForgivenessOfEmploymentObligationInConnectionsWithRestructuring	1526893	usd
CY2022	OCEL	Warrants Issued To Executives As Payment For Outstandings Compensation WarrantsIssuedToExecutivesAsPaymentForOutstandingsCompensation	649740	usd
CY2023	OCEL	Warrants Issued In Connection With Convertible Notes WarrantsIssuedInConnectionWithConvertibleNotes	72430	usd
CY2023	OCEL	Finance Lease Assigned To Buyer In Connection With Asset Sale FinanceLeaseAssignedToBuyerInConnectionWithAssetSale	213261	usd
CY2022	OCEL	Stock Issued In Exchange For Accounts Payable StockIssuedInExchangeForAccountsPayable	117500	usd
CY2023	OCEL	Oid Discount On Proceeds Received From Promissory Note OidDiscountOnProceedsReceivedFromPromissoryNote	10600	usd
CY2022	OCEL	Oid Discount On Proceeds Received From Promissory Note OidDiscountOnProceedsReceivedFromPromissoryNote	60000	usd
CY2022	OCEL	Stock Purchased From Payments Due On Accounts Payable StockPurchasedFromPaymentsDueOnAccountsPayable	20000	usd
CY2023	OCEL	Common Stock Issued As Commitment Fee For Promissory Note CommonStockIssuedAsCommitmentFeeForPromissoryNote	282500	usd
CY2022	OCEL	Common Stock Issued As Commitment Fee For Promissory Note CommonStockIssuedAsCommitmentFeeForPromissoryNote	156231	usd
CY2022	OCEL	Commitment Fee Shortfall Obligation CommitmentFeeShortfallObligation	143769	usd
CY2022	OCEL	Commitment To Repurchase Share In Connections With Settlement Of Litigation CommitmentToRepurchaseShareInConnectionsWithSettlementOfLitigation	-500000	usd
CY2022	OCEL	Promissory Note Issued For Past Due Professional Fees PromissoryNoteIssuedForPastDueProfessionalFees	256000	usd
CY2022	OCEL	Purchase Of Fixed Assets Included In Accounts Payable PurchaseOfFixedAssetsIncludedInAccountsPayable	77865	usd
CY2023	OCEL	Common Stock Issued In Satisfaction Of Commitment Fee Shortfall Obligation CommonStockIssuedInSatisfactionOfCommitmentFeeShortfallObligation	193379	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_zlKC8f5c2cU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 – <span id="xdx_820_zHdygcQhYjY8">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Organicell Regenerative Medicine, Inc. (“Organicell” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada under the name Bespoke Tricycles Inc. (changed to Biotech Products Services and Research, Inc. during September 2015 and to Organicell Regenerative Medicine, Inc., effective June 20, 2018). The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent (“RAAM Products”). Our RAAM Products and related services are principally used in the health care industry administered through doctors and clinics (“Providers”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 8, 2023, our board of directors and our stockholders holding a majority of the Company’s voting power, approved resolutions authorizing the Company to amend its Articles of Incorporation to change the name (“Name Change”) of the Company from Organicell Regenerative Medicine, Inc. to “Zeo ScientifiX, Inc.” Implementation and effectiveness of the Name Change will be subject to Organicell’s compliance with applicable regulatory requirements of the Securities and Exchange Commission and FINRA.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended October 31, 2023 and 2022, the Company principally operated through General Surgical of Florida, Inc., a Florida corporation and wholly owned subsidiary, which was formed to sell the Company’s therapeutic products to Providers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s leading product, Zofin™ (also known as Organicell™ Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recently launched a service platform for its first autologous product called Patient Pure X™ (PPX™). PPX™ is a non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood. To date, revenues from PPX™ continue to be minimal.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended October 31, 2023, the Company began to expand the use of its proprietary products in future formulations for a variety of topical use applications in the skin-care industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 7, 2023, the Company filed a certificate of amendment to its Articles of Incorporation to affect a reverse split of our issued and outstanding common stock on a one-for-two-hundred basis. The reverse stock split was effective with FINRA on November 28, 2023 (the “Reverse Split”). The par value of the Company’s common stock was unchanged at $0.001 per share after the Reverse Split. As a result, on the effective date of the Reverse Split, the stated capital on the Company’s balance sheet attributable to the Company’s common stock was reduced proportionately based on the reverse stock split ratio of one-for-two hundred and the additional paid-in capital account was credited with the amount by which the stated capital was reduced. All per share amounts referenced herein are reflective of the Reverse Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zYZrwMzgS0ed" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86E_zirgFw1cRGv3">Concentrations of Risk</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_c20231031_pp0p0" title="FDIC limits per institutions">250,000</span> per institution. At October 31, 2023, the Company held in two financial institutions a total of $<span id="xdx_907_eus-gaap--CashUninsuredAmount_c20231031_pp0p0" title="Cash Balances">915,497</span> of cash balances in excess of FDIC insurance coverage limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Major Customer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended October 31, 2023, the Company sold products and services totaling approximately $<span id="xdx_90C_eus-gaap--Revenues_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorAndDistributorsCustomersMember_pp0p0" title="Revenues">1,301,000</span> (<span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorAndDistributorsCustomersMember_pdd" title="Concentration credit risk percentage">28.5%</span>) to a large distributor and the distributor’s customers, approximately $<span id="xdx_905_eus-gaap--Revenues_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ALargeDistributorAndTheDistributorsCustomersMember_pp0p0" title="Revenues">459,000</span> (<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ALargeDistributorAndTheDistributorsCustomersMember_pdd" title="Concentration credit risk percentage">10.1%</span>) to a large distributor and the distributor’s customers and approximately $<span id="xdx_901_eus-gaap--Revenues_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--IndividualMedicalPracticeMember_pp0p0" title="Revenues">460,000</span> (<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--IndividualMedicalPracticeMember_pdd" title="Concentration credit risk percentage">10.1%</span>) to an individual medical practice.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended October 31, 2022, the Company sold a total of approximately $<span id="xdx_90E_eus-gaap--Revenues_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorAndDistributorsCustomersMember_pp0p0" title="Revenues">2,124,000</span> (<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorAndDistributorsCustomersMember_pdd" title="Concentration credit risk percentage">32.7%</span>) to a large distributor and the distributors customers, approximately $<span id="xdx_900_eus-gaap--Revenues_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOfAnotherDistributorMember_pp0p0" title="Revenues">1,413,700</span> (<span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOfAnotherDistributorMember_pdd" title="Concentration credit risk percentage">21.8%</span>) to customers of another distributor and $<span id="xdx_904_eus-gaap--Revenues_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManagementServicesOrganizationMember_pp0p0" title="Revenues">702,100</span> (<span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ManagementServicesOrganizationMember_pdd" title="Concentration credit risk percentage">10.8%</span>) of product to a management services organization (MSO) that provides administrative services and contracts for medical supplies for several medical practices.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Major Supplier</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended October 31, 2023, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $<span id="xdx_90F_eus-gaap--CostOfRevenue_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstSupplierMember_pp0p0" title="Cost of revenues">113,100</span> and $<span id="xdx_90B_eus-gaap--CostOfRevenue_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondSupplierMember_pp0p0" title="Cost of revenues">86,900</span> or <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstSupplierMember_pdd" title="Concentration credit risk percentage">57.0%</span> and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_c20221101__20231031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondSupplierMember_pdd" title="Concentration credit risk percentage">43.0%</span>, respectively, of the total amount of tissue raw material purchased during that period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended October 31, 2022, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $<span id="xdx_90D_eus-gaap--CostOfRevenue_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstSupplierMember_pp0p0" title="Cost of revenues">145,000</span> and $<span id="xdx_909_eus-gaap--CostOfRevenue_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondSupplierMember_pp0p0" title="Cost of revenues">130,000</span> or <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FirstSupplierMember_pdd" title="Concentration credit risk percentage">53.0%</span> and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_c20211101__20221031__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TissueRawMaterialMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondSupplierMember_pdd" title="Concentration credit risk percentage">47.0%</span>, respectively, of the total amount of tissue raw material purchased during that period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s supply agreements are non-exclusive and the Company does not believe it has any exposure based on the availability of raw materials and/or products from other suppliers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	915497	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zHw1fouycuk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_864_zrBmGAeVTz5">Use of Estimates</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6986708	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2197275	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57508014	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1241019	usd
CY2023	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	0	usd
CY2022	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	0	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	27500	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	37455	usd
CY2023Q4	OCEL	Working Capital Deficit WorkingCapitalDeficit	1807926	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	499216	shares
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	922700	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	791300	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	400100	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7283483	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7283483	shares
CY2023Q4	OCEL	Operating And Finance Lease Obligation OperatingAndFinanceLeaseObligation	15000	usd
CY2022Q3	OCEL	Letter Of Intent Description LetterOfIntentDescription	Skycrest/Greyt Group and Beyond 100 each advanced Organicell $400,000 and $300,000, respectively (a total of $700,000) as good faith deposits against the $2,000,000 (a total of $4,000,000) purchase price for the Shares.
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	153868	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	85096	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	156315	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	163414	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	310183	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	248510	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	794887	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2123170	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	222161	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	439654	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	572726	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1683516	usd
CY2023	us-gaap	Depreciation Depreciation	106384	usd
CY2022	us-gaap	Depreciation Depreciation	82036	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	379970	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	250472	usd
CY2023	OCEL	Stockbased Compensation StockbasedCompensation	834282	usd
CY2022	OCEL	Stockbased Compensation StockbasedCompensation	6609802	usd
CY2022	OCEL	Executive Forgiveness Of Employment Obligations In Connections With Restructuring ExecutiveForgivenessOfEmploymentObligationsInConnectionsWithRestructuring	480109	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	247612	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	249665	usd
CY2023Q4	OCEL	Equity In Nonmarketable Securities EquityInNonmarketableSecurities	100000	usd
CY2023Q4	OCEL	Reserve On Carrying Value Of Investment In Nonmarketable Securities ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities	-100000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	23588	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	5536	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	5536	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2768	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	37428	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1187	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	36241	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	29670	usd
CY2023	OCEL	Rent Expenses RentExpenses	0	usd
CY2022	OCEL	Rent Expenses RentExpenses	31500	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	0	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	36352	usd
CY2023	OCEL	Unpaid And Accrued Compensation Description UnpaidAndAccruedCompensationDescription	Ian Bothwell waived all unpaid and accrued compensation in the amount of $1,043,478, in exchange for ten-year warrants to purchase 150,000 Shares at an exercise price of $4.00 per share, exercisable on a “cashless basis” and a cash payment of $50,000 at Closing. At Closing, Dr. George Shapiro terminated his consulting arrangement with the Company and waived all unpaid consulting fee obligations in the amount of $139,500 in exchange for ten-year warrants to purchase 15,750 Shares at an exercise price of $4.00 per share, exercisable on a “cashless basis.”
CY2023	OCEL	Cash Invested In Nonmarketable Equity Securities CashInvestedInNonmarketableEquitySecurities	100000	usd
CY2023	OCEL	Option Acquire Description OptionAcquireDescription	the Company’s CMO was granted an option to acquire up to 200,000 membership interests in the Formulator, of which 100,000 vested immediately and the remaining $100,000 will vest based on future sales of the Formulator attributed to the CMO. The option price is $20,000 for the 200,000 membership interests (see Note 7).
CY2023Q4	OCEL	Advances Payable AdvancesPayable	220897	usd
CY2022Q4	OCEL	Advances Payable AdvancesPayable	220897	usd
CY2023	OCEL	Total Income Tax Expense Benefit TotalIncomeTaxExpenseBenefit	-734650	usd
CY2022	OCEL	Total Income Tax Expense Benefit TotalIncomeTaxExpenseBenefit	5484844	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	734650	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5484844	usd
CY2023Q4	OCEL	Federal Operating Loss Carryforwards FederalOperatingLossCarryforwards	17196794	usd
CY2023Q4	OCEL	State Operating Loss Carryforwards StateOperatingLossCarryforwards	12025813	usd
CY2023Q4	OCEL	State Operating Loss Carryforward Indefinitely StateOperatingLossCarryforwardIndefinitely	6554845	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	11.35
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	666924	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	666780	usd
CY2023Q4	OCEL	Lab Equipment And Supplies Payables LabEquipmentAndSuppliesPayables	407183	usd
CY2022Q4	OCEL	Lab Equipment And Supplies Payables LabEquipmentAndSuppliesPayables	477255	usd
CY2023Q4	OCEL	Clinical Trial Payables ClinicalTrialPayables	675284	usd
CY2022Q4	OCEL	Clinical Trial Payables ClinicalTrialPayables	312711	usd
CY2023Q4	OCEL	Legal Fees Payables LegalFeesPayables	478810	usd
CY2022Q4	OCEL	Legal Fees Payables LegalFeesPayables	328121	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	81135	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	90993	usd
CY2023Q4	OCEL	Accrued Irs Penalty AccruedIrsPenalty	86319	usd
CY2022Q4	OCEL	Accrued Irs Penalty AccruedIrsPenalty	83684	usd
CY2023Q4	OCEL	Accrued Commissions Payable AccruedCommissionsPayable	101627	usd
CY2022Q4	OCEL	Accrued Commissions Payable AccruedCommissionsPayable	39675	usd
CY2023Q4	OCEL	Construction Payables ConstructionPayables	9317	usd
CY2022Q4	OCEL	Construction Payables ConstructionPayables	5474	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	105370	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	373838	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2611969	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2378531	usd
CY2022Q2	OCEL	Lawsuit Settlement By Cash LawsuitSettlementByCash	45000	usd
CY2022Q2	OCEL	Lawsuit Settlement By Issuance Of Restricted Common Stock LawsuitSettlementByIssuanceOfRestrictedCommonStock	10000	shares
CY2022Q2	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	43800	usd
CY2022Q4	OCEL	Number Of Common Stock Repurchase NumberOfCommonStockRepurchase	124000	shares
CY2022Q4	OCEL	Repurchase Value RepurchaseValue	500000	shares
CY2022Q4	OCEL	Securities Purchase Agreement22 SecuritiesPurchaseAgreement22	600000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	725000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	68147	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	36889	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	656853	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	563111	usd
CY2022Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
CY2023	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	300000	usd
CY2023Q1	us-gaap	Contractual Obligation ContractualObligation	187519	usd
CY2023Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	58600	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	3.20
CY2023Q1	OCEL	Commitment Fee CommitmentFee	30468	usd
	us-gaap	Legal Fees LegalFees	15000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	504400	usd
CY2023	OCEL	Debt Amortized Discount DebtAmortizedDiscount	308000	usd
CY2023	OCEL	Schedule Of Provision For Income Tax Table Taxt Block ScheduleOfProvisionForIncomeTaxTableTaxtBlock	<table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfProvisionForIncomeTaxTableTaxtBlock_z8mH90gSNBn3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span id="xdx_8B2_zowWHrpS5yba" style="display: none">Schedule of provision for income tax</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_494_20221101__20231031_zsR1dlb95Hvl" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20211101__20221031_zauWvnodWHNe" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended <br/> October 31,<br/> 2023</span></td> <td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended <br/> October 31,<br/> 2022</span></td> <td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current:</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_maCITEBz1Ra_zzPK1BAnTsmj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_maCITEBz1Ra_zXrbJZqYfoDb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_mtCITEBz1Ra_zoDGDKCtgDwd" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="color: White; font-family: Times New Roman, Times, Serif"> Current Income Tax Expense (Benefit)</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredIncomeTaxesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred:</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzLaW_z0ZpFxvGGoek" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(385,315</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,405,121</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0p0_maDITEBzLaW_zzYmfyWDj6a6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(349,335</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,079,723</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_mtDITEBzLaW_zbplj4FNuKe6" style="vertical-align: bottom; background-color: White"> <td style="color: White; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Deferred Income Tax Expense (Benefit)</td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(734,650</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,484,844</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_i01N_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Change in Valuation Allowance</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">734,650</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,484,844</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_i01_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="color: White; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Income tax provision<span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table>
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-385315	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	4405121	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-349335	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1079723	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-734650	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5484844	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	734650	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5484844	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1467209	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1868277	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-349335	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-386555	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1636853	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	798239	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	3611327	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	3002402	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	617525	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	396530	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1477	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5865705	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4198648	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	309260	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	302447	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	309260	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	302447	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5556445	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3896201	usd
CY2023	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	90000	usd
CY2011	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	20000	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	86319	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	83684	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000	shares
CY2021Q2	us-gaap	Share Price SharePrice	27.20
CY2021Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	136000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100211	usd
CY2021Q4	OCEL	Annual Salary AnnualSalary	180000	usd
CY2021Q4	OCEL	Increasing Annual Salary IncreasingAnnualSalary	210000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	5000	shares
CY2021Q4	us-gaap	Share Price SharePrice	5.80
CY2021Q4	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	29000	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22958	usd
CY2021Q4	OCEL	Cash Provided For Credit Facility CashProvidedForCreditFacility	0	usd
CY2021Q4	OCEL	Purchase Of Restricted Common Shares PurchaseOfRestrictedCommonShares	35000	shares
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.00
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	15000	shares
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	201000	usd
CY2022Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	15385	shares
CY2023Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	75000	shares
CY2023Q1	OCEL	Common Stock Issued As Commitment Fee For Promissory Note CommonStockIssuedAsCommitmentFeeForPromissoryNote	169500	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	169983	shares
CY2023	OCEL	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Vested Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateVestedFairValue	12.19
CY2023	OCEL	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeiture In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitureInPeriod	229233	shares
CY2023	OCEL	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.35
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	100000	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	12.20
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	419222	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	12.34
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	129500	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.86
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	49506	shares
CY2022	OCEL	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Vested Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateVestedFairValue	7.98
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	499216	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	11.35
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4881000	usd
CY2023Q4	OCEL	Due From Related Party DueFromRelatedParty	0	usd
CY2022Q4	OCEL	Due From Related Party DueFromRelatedParty	128939	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	7233	shares
CY2022Q4	OCEL	Vested Salary Shares VestedSalaryShares	40767	shares
CY2023Q4	OCEL	Contract Research Organization Outstanding ContractResearchOrganizationOutstanding	587800	usd
CY2022Q4	OCEL	Contract Research Organization Outstanding ContractResearchOrganizationOutstanding	244900	usd
CY2023	OCEL	Lawsuit Settlement By Cash LawsuitSettlementByCash	45000	usd
CY2023	OCEL	Lawsuit Settlement By Issuance Of Restricted Common Stock LawsuitSettlementByIssuanceOfRestrictedCommonStock	2000000	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer

Files In Submission

Name	View Source	Status
ocel-20231031_cal.xml	Edgar Link	unprocessable
ocel-20231031_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001829126-24-000541-index-headers.html	Edgar Link	pending
0001829126-24-000541-index.html	Edgar Link	pending
0001829126-24-000541.txt	Edgar Link	pending
0001829126-24-000541-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ocel-20231031.xsd	Edgar Link	pending
organicellregen_10k.htm	Edgar Link	pending
organicellregen_ex23-1a.htm	Edgar Link	pending
organicellregen_ex23-1b.htm	Edgar Link	pending
organicellregen_ex31-1.htm	Edgar Link	pending
organicellregen_ex31-2.htm	Edgar Link	pending
organicellregen_ex32-1.htm	Edgar Link	pending
organicellregen_ex32-2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
ocel-20231031_pre.xml	Edgar Link	unprocessable
ocel-20231031_lab.xml	Edgar Link	unprocessable
organicellregen_10k_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZEOX
Zeo ScientifiX, Inc. Stock $zeox

2024 Q1 Form 10-K Financial Statement

#000182912624000541 Filed on January 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZEOX Zeo ScientifiX, Inc. Stock $zeox

2024 Q1 Form 10-K Financial Statement

#000182912624000541 Filed on January 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZEOX
Zeo ScientifiX, Inc. Stock $zeox